Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

RBOT.WS vs ENOV: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ENOV Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 9–1 Matrix Metrics)

ENOV Overall Winner 6-Pillar Tally: RBOT.WS 0 – 5 ENOV (1 Tie) Matrix Metrics: RBOT.WS 1 – 9 ENOV

As of Nov 20, 2026, Enovis Corporation (ENOV) is the stronger overall head-to-head candidate over Vicarious Surgical Inc. Warrants, each whole warrant exercisable for 1/30th of a share of (RBOT.WS) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). RBOT.WS carries a Unified Composite Score of 50.1/100 (HOLD) at $0.01 (N/M Forward P/E, N/A operating margin), whereas ENOV carries 30.0/100 (SELL) at $25.47 (7.3x Forward P/E, 4.0% operating margin).

  • Composite vs. Pillar Nuance: While RBOT.WS currently prints a higher short-term Unified Composite Score (50.1/100 HOLD vs. ENOV 30.0/100 SELL), ENOV captures the overall institutional head-to-head verdict (9–1 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (4.0% vs. N/A operating margin) and revenue trajectory (+1.8% vs. N/A YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About RBOT.WS vs ENOV
RBOT.WS NYSE
Vicarious Surgical Inc. Warrants, each whole warrant exercisable for 1/30th of a share of Class A Common Stock at an exercise price of $345.00
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$0.01
-24.77% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol N/A
Unified Composite Score
50.1 / 100 HOLD
Tech 40.0 Fund 46.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Trend telemetry aligned with daily close.
RSI-14: N/A · SMA20: N/A · SMA50: N/A
ENOV NYSE Head-to-Head Winner
Enovis Corporation
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$25.47
-2.9% 1D
Market Cap $1.5B
TTM Revenue $2.31B
Forward P/E 7.3x
Beta / 30D Vol 0.75β · 101% Vol
Unified Composite Score
30.0 / 100 SELL
Tech 15.0 Fund 28.0 Flow 50.0 Mom 21.3
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (4.2% over 20 days), RSI 54
RSI-14: 54.3 · SMA20: $25.18 · SMA50: $21.30

6-Pillar Scorecard Institutional Category Breakdown (RBOT.WS 0 – 5 ENOV)

Columns: Metric · RBOT.WS · ENOV
1. Valuation Multiples ENOV
Forward P/E N/M 7.3x
Trailing P/E N/M 7.5x
PEG Ratio N/M 1.90x
EV / Revenue N/M 0.7x
2. Growth & Scale ENOV
Revenue Growth (YoY) N/A +1.8%
Earnings Growth (YoY) N/A +153.1%
TTM Revenue (USD) N/A $2.31B
Market Cap N/A $1.5B
3. Profitability & Quality ENOV
Gross Margin N/A 61.3%
Operating Margin N/A 4.0%
Net Profit Margin N/A -22.9%
Return on Equity (ROE) N/A -29.9%
4. Balance Sheet & Cash Flow ENOV
Cash Generation (TTM) N/A $387M EBITDA
Cash Flow Margin N/A 16.8% EBITDA Mgn
Net Cash / Leverage N/A ROE $25.88 Book/Sh · -29.9% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 65.6% (43rd %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markup
6. R&D & Supply-Chain Moat ENOV
OpEx & R&D Intensity N/A 57.3% of Rev ($1.32B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Orthopedic, Prosthetic & Surgical Appliances & Supplies Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: RBOT.WS (1) vs ENOV (9)
Institutional Metric RBOT.WS ENOV Criterion Row Edge
Market Capitalization
Scale
N/A $1.5B Larger Scale ENOV
Trailing P/E Ratio
Valuation
N/M 7.5x Lower Multiple ENOV
Forward P/E Ratio
Valuation
N/M 7.3x Lower Multiple ENOV
Revenue Growth (YoY)
Growth
N/A +1.8% Higher Growth ENOV
Operating Margin (TTM)
Profitability
N/A 4.0% Higher Margin ENOV
Net Profit Margin
Profitability
N/A -22.9% Higher Margin ENOV
Return on Equity (ROE)
Capital Efficiency
N/A -29.9% Higher ROE ENOV
52-Week Range Position
Momentum
0% ($0–$0) 59% ($17–$32) Stronger Trend ENOV
Beta / 30D Volatility
Risk Regime
N/A 0.75β · 101% Vol Lower Realized Risk ENOV
Unified Institutional Score
Composite Signal
50.1 / 100 (HOLD) 30.0 / 100 (SELL) Higher Composite RBOT.WS
Trailing 12M Revenue (USD)
Operating Scale
N/A $2.31B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 61.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 1.90x PEG · 0.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) $387M EBITDA ($25.88 Book/Sh · -29.9% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ENOV +65.93 pp
RBOT.WS: -67.2% · ENOV: -1.27%
3M Horizon ENOV +65.93 pp
RBOT.WS: -67.2% · ENOV: -1.27%
6M Horizon ENOV +65.93 pp
RBOT.WS: -67.2% · ENOV: -1.27%
1Y Horizon ENOV +65.93 pp
RBOT.WS: -67.2% · ENOV: -1.27%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on RBOT.WS vs ENOV. Trailing 12-month operating profitability (RBOT.WS N/A vs ENOV 4.0%) and valuation multiples (RBOT.WS N/M vs ENOV 7.3x Forward P/E) are benchmarked directly in Pillar 4 below.

RBOT.WS ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
ENOV ADR TTM Benchmark FX-Normalized USD
TTM Revenue$2.31B
Gross Margin61.3%
Op. Margin4.0%
ROE / Fwd P/E-29.9% · 7.3x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
RBOT.WS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact RBOT.WS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ENOV UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 65.6%
IV Percentile 43rd %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ENOV Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
RBOT.WS Moat Profile Cyclical / Execution-Driven Positioning
Orthopedic, Prosthetic & Surgical Appliances & Supplies Operator
Competes within the Orthopedic, Prosthetic & Surgical Appliances & Supplies value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ENOV Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $1.5B market capitalization and 4.0% operating margin.
OpEx & R&D Reinvestment 57.3% of Rev ($1.32B)
90D Engineering Disclosures 0 Published

Investor FAQ RBOT.WS vs ENOV Key Questions & Quantitative Answers

As of Nov 20, 2026, Enovis Corporation (ENOV) is the stronger overall head-to-head candidate over Vicarious Surgical Inc. Warrants, each whole warrant exercisable for 1/30th of a share of (RBOT.WS) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). RBOT.WS carries a Unified Composite Score of 50.1/100 (HOLD) at $0.01 (N/M Forward P/E, N/A operating margin), whereas ENOV carries 30.0/100 (SELL) at $25.47 (7.3x Forward P/E, 4.0% operating margin). Composite vs. Pillar Nuance: While RBOT.WS currently prints a higher short-term Unified Composite Score (50.1/100 HOLD vs. ENOV 30.0/100 SELL), ENOV captures the overall institutional head-to-head verdict (9–1 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (4.0% vs. N/A operating margin) and revenue trajectory (+1.8% vs. N/A YoY).

ENOV leads the Growth & Scale pillar: RBOT.WS posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with ENOV at +1.8% YoY revenue growth and +153.1% YoY earnings growth on $2.31B TTM revenue (61.3% gross margin, 4.0% operating margin). On trailing 12-month operating scale, RBOT.WS generates N/A in USD-normalized revenue versus $2.31B for ENOV. In operating R&D and SG&A reinvestment, RBOT.WS deploys N/A (0 90-day corporate R&D disclosures) versus 57.3% of Rev ($1.32B) (0 disclosures) for ENOV.

ENOV screens cheaper on headline valuation multiples. RBOT.WS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas ENOV trades at 7.3x Forward P/E, 7.5x Trailing P/E, 1.90x PEG, and 0.7x EV/Revenue (16.8% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RBOT.WS (N/A ROE) versus ENOV (-29.9% ROE) capital efficiency.

In options market volatility and institutional positioning, RBOT.WS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (N/A realized risk). By comparison, ENOV carries 65.6% implied volatility (43rd %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.75β · 101% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Vicarious Surgical Inc. Warrants, each whole warrant exercisable for 1/30th of a share of Class A Common Stock at an exercise price of $345.00 (RBOT.WS) Research Suite

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.